Spatial-Temporal Patterns of β-Amyloid Accumulation: A Subtype and Stage Inference Model Analysis
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Background and Objectives β-amyloid (Aβ) staging models assume a single spatial-temporal progression of amyloid accumulation. We assessed evidence for Aβ accumulation subtypes by applying the data-driven Subtype and Stage Inference (SuStaIn) model to amyloid-PET data. Methods Amyloid-PET data of 3,010 participants were pooled from 6 cohorts (ALFA+, EMIF-AD, ABIDE, OASIS, and ADNI). Standardized uptake value ratios were calculated for 17 regions. We applied the SuStaIn algorithm to identify consistent subtypes in the pooled dataset based on the cross-validation information criterion and the most probable subtype/stage classification per scan. The effects of demographics and risk factors on subtype assignment were assessed using multinomial logistic regression. Results Participants were mostly cognitively unimpaired (n = 1890 [62.8%]), had a mean age of 68.72 (SD 9.1) years, 42.1% were APOE ε4 carriers, and 51.8% were female. A 1-subtype model recovered the traditional amyloid accumulation trajectory, but SuStaIn identified 3 optimal subtypes, referred to as frontal, parietal, and occipital based on the first regions to show abnormality. Of the 788 (26.2%) with strong subtype assignment (>50% probability), the majority was assigned to frontal (n = 415 [52.5%]), followed by parietal (n = 199 [25.3%]) and occipital subtypes (n = 175 [22.2%]). Significant differences across subtypes included distinct proportions of APOE ε4 carriers (frontal 61.8%, parietal 57.1%, occipital 49.4%), participants with dementia (frontal 19.7%, parietal 19.1%, occipital 31.0%), and lower age for the parietal subtype (frontal/occipital 72.1 years, parietal 69.3 years). Higher amyloid (Centiloid) and CSF p-tau burden was observed for the frontal subtype; parietal and occipital subtypes did not differ. At follow-up, most participants (81.1%) maintained baseline subtype assignment and 25.6% progressed to a later stage. Discussion Whereas a 1-trajectory model recovers the established pattern of amyloid accumulation, SuStaIn determined that 3 subtypes were optimal, showing distinct associations with Alzheimer disease risk factors. Further analyses to determine clinical utility are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Desikan, R. S., Ségonne, F., Fischl, B., Quinn, B. T., Dickerson, B. C., Blacker, D., Buckner, R. L., Dale, A. M., Maguire, R. P., Hyman, B. T., et al. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.01.021 · Cited by 13,324 · cited 1×
“PET Quantification For all cohorts, standard uptake value ratios (SUVRs) relative to the cerebellar gray matter were available for all DesikanKilliany atlas regions.(21) For the purposes of this work, a set of 17 regions of interest (ROIs) was constructed by volumeweighted averaging of anatomically adjacent regions.”
The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348 · cited 3×
“This was done to account for not only tracer differences, but also for the differential signal distortion effects between medial and lateral regions (inherit to the PET metric),(4) which is not taken into account in the CL approach.(22) Third, whereas our initial results suggest robust assignment over time (i.”
InfluentialTau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease
Ossenkoppele, R., Schonhaut, D. R., Schöll, M., Lockhart, S. N., Ayakta, N., Baker, S. L., O’Neil, J. P., Janabi, M., Lazaris, A., Cantwell, A., et al. (2016) · Brain · doi:10.1093/brain/aww027 · Cited by 1,185
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
Four distinct trajectories of tau deposition identified in Alzheimer’s disease
Initiative, T. A. D. N., Vogel, J. W., Young, A. L., Oxtoby, N. P., Smith, R., Ossenkoppele, R., Strandberg, O. T., La Joie, R., Aksman, L. M., Grothe, M. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01309-6 · Cited by 741 · cited 2×
“More recent work identified 4 distinct spatiotemporal phenotypes of tau accumulation, which were associated with different clinical profiles and longitudinal cognitive outcomes, suggesting the value of such models for improving individualized prognosis and clinical care.(13) In the context of amyloid, previous descrip…”
Self-citationFlorbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study
Sabri, O., Sabbagh, M. N., Seibyl, J., Barthel, H., Akatsu, H., Ouchi, Y., Senda, K., Murayama, S., Ishii, K., Takao, M., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.004 · Cited by 602
Young, A. L., Marinescu, R. V., Oxtoby, N. P., Bocchetta, M., Yong, K., Firth, N. C., Cash, D. M., Thomas, D. L., Dick, K. M., Cardoso, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05892-0 · Cited by 596 · cited 4×
“A complete mathematical description of the SuStaIn algorithm is available.(11) The number of subtypes was iteratively increased, and the model chosen for further analysis was selected based on the CVIC.”
InfluentialChételat, G., Arbizu, J., Barthel, H., Garibotto, V., Law, I., Morbelli, S., van de Giessen, E., Agosta, F., Barkhof, F., Brooks, D. J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30314-8 · Cited by 526 · cited 1×
“Also, (posterior) amyloid burden is observed in approximately 50% of patients with dementia with Lewy bodies (DLB), which is suggested to reflect AD copathology and is associated with a worse prognosis.(30) A post hoc analysis of subtype classification in specifically the clinical ABIDE cohort provides further support…”
Self-citationIn vivo staging of regional amyloid deposition
Grothe, M. J., Barthel, H., Sepulcre, J., Dyrba, M., Sabri, O., Teipel, S. J., Initiative, F. T. A. D. N., Initiative, A. D. N., Weiner, M., Aisen, P., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004643 · Cited by 440
Self-citation
Cited by
Veitch, D. P., Weiner, M. W., Miller, M., Aisen, P. S., Ashford, M. A., Beckett, L. A., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13449 · Cited by 113
Artificial intelligence for dementia drug discovery and trials optimization
Doherty, T., Yao, Z., Khleifat, A. A. L., Tantiangco, H., Tamburin, S., Albertyn, C., Thakur, L., Llewellyn, D. J., Oxtoby, N. P., Lourida, I., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13428 · Cited by 48
Schworer, E. K., Zammit, M. D., Wang, J., Handen, B. L., Betthauser, T., Laymon, C. M., Tudorascu, D. L., Cohen, A. D., Zaman, S. H., Ances, B. M., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00426-5 · Cited by 29
Identifying progression-specific Alzheimer’s subtypes using multimodal transformer
Machado Reyes, D., Chao, H., Hahn, J., Shen, L., Yan, P., & Initiative, F. T. A. D. N. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14040421 · Cited by 17
“AD subtypes have been previously identified based on hallmark AD biomarkers obtained from brain imaging such as beta-amyloid [12] and tau accumulation [13,14].”
A review of neuroimaging-based data-driven approach for Alzheimer’s disease heterogeneity analysis
Liu, L., Sun, S., Kang, W., Wu, S., & Lin, L. (2024) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0033 · Cited by 16
“Collij et al. (2022) further utilized SuStaIn to analyze A β -protein accumulation subtypes based on amyloid-PET data, identifying three subtypes named the frontal, apical, and occipital subtypes.”
Method
Metadata
- Authors
- Collij, L. E., Salvadó, G., Wottschel, V., Mastenbroek, S. E., Schoenmakers, P., Heeman, F., Aksman, L., Wink, A. M., Berckel, B. N. M., van de Flier, W. M., Scheltens, P., Visser, P. J., Barkhof, F., Haller, S., Gispert, J. D., Lopes Alves, I., & study, F. T. A. D. N. I. F. T. A.
- Venue
- Neurology
- Published
- 2022-04-26
- Volume
- 98
- Issue
- 17
- Pages
- e1692-e1703
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W4220802700
- Cited by
- 97
- References
- 16
- FWCI
- 11.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Spatial-Temporal Patterns of β-Amyloid Accumulation: A Subtype and Stage Inference Model Analysis. https://app.cochat.ai/papers/10.1212/wnl.0000000000200148
- The paper
- Collij, L. E., Salvadó, G., Wottschel, V., Mastenbroek, S. E., Schoenmakers, P., Heeman, F., Aksman, L., Wink, A. M., Berckel, B. N. M., van de Flier, W. M., Scheltens, P., Visser, P. J., Barkhof, F., Haller, S., Gispert, J. D., Lopes Alves, I., & study, F. T. A. D. N. I. F. T. A. (2022). Spatial-Temporal Patterns of β-Amyloid Accumulation: A Subtype and Stage Inference Model Analysis. Neurology. https://doi.org/10.1212/wnl.0000000000200148
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.